Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan
Human papillomavirus (HPV) vaccination has not been introduced in many countries in South-Central Asia, including Afghanistan, despite the sub-region having the highest incidence rate of cervical cancer in Asia. This study estimates the potential health impact and cost-effectiveness of HPV vaccinati...
Full description
| Author: |
|---|
| Format: |
Electronic Article |
|---|---|
| Language: |
English |
| Physical Description: |
Online-Ressource |
|---|
| Containing Work: |
In: Vaccine - Amsterdam : Elsevier, Vol. 38, No. 6 (2020), p. 1352-1362 |
|---|
| Links: |
|---|
| DOI / URN: |
10.1016/j.vaccine.2019.12.013 |
|---|
| Catalog id: |
ELV042230276 |
|---|
| LEADER | 01783nma a2200385 c 4500 | ||
|---|---|---|---|
| 001 | ELV042230276 | ||
| 003 | DE-601 | ||
| 005 | 20200518172205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200518s2020 000 0 eng d | ||
| 016 | 7 | |a 1468474-3 |2 DE-600 | |
| 024 | 7 | |a 10.1016/j.vaccine.2019.12.013 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000000920.pica |
| 035 | |a S0264-410X(19)31655-X | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Anwari, Palwasha | |
| 245 | 1 | 0 | |a Potential health impact and cost-effectiveness of bivalent human papillomavirus (HPV) vaccination in Afghanistan |h Elektronische Ressource |
| 300 | |a Online-Ressource | ||
| 520 | |a Human papillomavirus (HPV) vaccination has not been introduced in many countries in South-Central Asia, including Afghanistan, despite the sub-region having the highest incidence rate of cervical cancer in Asia. This study estimates the potential health impact and cost-effectiveness of HPV vaccination in Afghanistan to inform national decision-making. | ||
| 700 | 1 | |a Debellut, Frédéric | |
| 700 | 1 | |a Vodicka, Elisabeth | |
| 700 | 1 | |a Clark, Andrew | |
| 700 | 1 | |a Farewar, Farhad | |
| 700 | 1 | |a Zhwak, Zubiada A. | |
| 700 | 1 | |a Nazary, Dastagger | |
| 700 | 1 | |a Pecenka, Clint | |
| 700 | 1 | |a Scott LaMontagne, D. | |
| 700 | 1 | |a Safi, Najibullah | |
| 773 | 0 | 8 | |i In |t Vaccine |d Amsterdam : Elsevier |g Vol. 38, No. 6 (2020), p. 1352-1362 |q 38:6<1352-1362 |w (DE-601)ELV007884451 |w S0264-410X(19)X0054-7 |x 1873-2518 |
| 856 | 4 | 1 | |u https://doi.org/10.1016/j.vaccine.2019.12.013 |3 Volltext |
| 912 | |a GBV_ELV | ||
| 950 | |a Cost-effectiveness analysis |a Human papillomavirus |a Afghanistan |a HPV vaccine |a Cervical cancer |2 Elsevier | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2020 |e 6 |b 5 |c 0205 |h 1352-1362 |g 11 | ||